DBV Technologies (NASDAQ:DBVT) Downgraded to “Sell” Rating by Wall Street Zen

DBV Technologies (NASDAQ:DBVT) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

Several other research analysts have also recently issued reports on the company. Citigroup reissued an “outperform” rating on shares of DBV Technologies in a research note on Wednesday, December 17th. Citizens Jmp increased their price target on DBV Technologies from $21.00 to $45.00 and gave the stock a “market outperform” rating in a research report on Wednesday, December 17th. Weiss Ratings restated a “sell (e+)” rating on shares of DBV Technologies in a research note on Monday, December 29th. HC Wainwright set a $40.00 price objective on shares of DBV Technologies in a research note on Thursday, December 18th. Finally, Guggenheim reiterated a “buy” rating and set a $51.00 target price (up from $35.00) on shares of DBV Technologies in a report on Wednesday, December 17th. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, DBV Technologies currently has an average rating of “Moderate Buy” and a consensus target price of $35.38.

DBV Technologies Price Performance

Shares of DBVT opened at $21.61 on Friday. The firm has a market capitalization of $867.86 million, a price-to-earnings ratio of -4.18 and a beta of -1.17. DBV Technologies has a 1-year low of $3.80 and a 1-year high of $26.18. The company has a 50-day moving average of $18.47 and a 200 day moving average of $13.96.

Insider Activity

In other news, major shareholder Bpifrance Epic sold 2,076,990 shares of DBV Technologies stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $4.85, for a total value of $10,073,401.50. Following the transaction, the insider owned 8,595,472 shares of the company’s stock, valued at $41,688,039.20. The trade was a 19.46% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 1.44% of the stock is currently owned by insiders.

Hedge Funds Weigh In On DBV Technologies

Several institutional investors and hedge funds have recently bought and sold shares of DBVT. New York State Common Retirement Fund acquired a new position in shares of DBV Technologies during the third quarter worth $34,000. GAMMA Investing LLC grew its stake in DBV Technologies by 38.4% during the 4th quarter. GAMMA Investing LLC now owns 2,680 shares of the company’s stock worth $51,000 after buying an additional 744 shares during the last quarter. Two Sigma Investments LP acquired a new position in DBV Technologies during the 3rd quarter valued at about $167,000. Citadel Advisors LLC acquired a new position in DBV Technologies during the 3rd quarter valued at about $220,000. Finally, DLD Asset Management LP purchased a new stake in DBV Technologies in the third quarter valued at about $250,000. 71.74% of the stock is owned by hedge funds and other institutional investors.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.